An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma
Status:
Completed
Trial end date:
2019-05-22
Target enrollment:
Participant gender:
Summary
This open-label, single-arm, multicenter study will assess the safety and efficacy of
Zelboraf (vemurafenib) in patients with Braf V600 mutation positive metastatic melanoma.
Patients will receive Zelboraf 960 mg twice a day until progressive disease, unacceptable
toxicity, consent withdrawal, death, reasons deemed by the treating physician or study
termination.